Research Progress on Placental Growth Factor and Tumor_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LUOJin-long ¹ ,  JIANGHuai-wu ²

1. Department of General Surgery, Affiliated Hospital of Luzhou Medical College, Luzhou 646000, Sichuan Province, China;
2. Department of Gastrointestinal Surgery, The Second Affiliated Hospital of North Sichuan Medical College(Sichuan Mianyang 404 Hospital), Mianyang 621000, Sichuan Province, China;

Corresponding?author：

JIANGHuai-wu, Email: jhuaiwu@163.com

Keywords：

Placental growth factor; Tumor; Research progress

DOI：

10.7507/1007-9424.20140251

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To understand the role of placental growth factor (PlGF) in occurrence and development of tumor. Method The literatures related to biological function and research progress of PlGF in tumor in recent years were reviewed. Results PlGF was a secreted homology dimeric glycoprotein, with the regulation function on trophoblast cell, could induce inflammation reaction．It highly expressed in many tumor tissues, could promote the tumor growth and angiogenesis. The PlGF antibody treatment had a certain therapeutic effect, but it was still in clinical trials. Conclusions Although there are some disputes about conclusions on the role of PlGF in tumor, but it is obvious for the advantage in tumor treatment. With the research progress on PlGF, PlGF might be a breakthrough for tumor treatment．

Citation： LUOJin-long, JIANGHuai-wu. Research Progress on Placental Growth Factor and Tumor. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(8): 1046-1050. doi: 10.7507/1007-9424.20140251 Copy

1.	胡玉弘, 趙志國, 楊松梅, 等.血管內皮生長因子基因多態性與惡性腫瘤關系研究進展[J].河北醫學, 2010, 16(2):233-235.
2.	Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels[J]. Cell, 2007, 131(3):463-475.
3.	蔡源源, 李光早.血管內皮生長因子的調控及其作用研究進展[J].組織工程與外科重建雜志, 2010, 7(1):51-54.
4.	Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14[J]. Oncogene, 1993, 8(4):925-931.
5.	De Falco S. The discovery of placenta growth factor and its biological activity[J]. Exp Mol Med, 2012, 44(1):1-9.
6.	Errico M, Riccioni T, Iyer S, et al. Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor[J]. J Biol Chem, 2004, 279(42):43929-43939.
7.	時瑩慶, 關巍.胎盤生長因子與低氧的關系研究進展[J].中國醫療前沿, 2013, 8(4):7-8.
8.	何云, 鐘梅, 王晨虹.胎盤生長因子及相關研究[J].醫學綜述, 2011, 17(13):1936-1939.
9.	Schomber T, Kopfstein L, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis[J]. Cancer Res, 2007, 67(22):10840-10848.
10.	Shibuya M. Vascular endothelial growth factor receptor-1(VEGFR-1/ Flt-1):a dual regulator for angiogenesis[J]. Angiogenesis, 2006, 9(4):225-230.
11.	Boyaud F, Inguimbert N. Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)[J]. Expert Opinion on Therapeutic Patents, 2011, 971-975.
12.	Zhou Y, Mcmaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome[J]. Am J Pathol, 2002, 160(4):1405-1423.
13.	Ribatti D. The discovery of the placental growth factor and its role in angiogenesis:a historical review[J]. Angiogenesis, 2008, 11(3):215-221.
14.	李慧娟, 楊文浩, 崔劉福.胎盤生長因子及其受體在類風濕性關節炎發病機制中的作用[J].中國醫藥, 2010, 5(4):376-377.
15.	Yoo SA, Yoon HJ, Kim HS, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation:a link between angiogenesis and inflammation[J]. Arthritis Rheum, 2009, 60(2):345-354.
16.	Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation[J]. Blood, 2003, 101(2):560-567.
17.	Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability[J]. J Cell Sci, 2002, 115(Pt 12):2559-2567.
18.	Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF[J]. Cancer Cell, 201l, 19(1):31-44.
19.	閆鵬飛, 李煜.胎盤生長因子的生物活性及其與腫瘤相關作用的研究進展[J].藥物生物技術, 2012, 19(30):265-269.
20.	Jain RK, Xu LL. AlphaPlGF:a new kid on the antiangiogenesis block[J]. Cell, 2007, 131(3):443-445.
21.	Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions[J]. Nat Med, 2001, 7(5):575-583.
22.	Papapetropoulos A, García-Carde?a G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells[J]. J Clin Invest, 1997, 100(12):3131-3139.
23.	Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1[J]. Nat Med, 2003, 9(7):936-943.
24.	Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor[J]. Am J Pathol, 2006, 169(2):643-654.
25.	Wei SC, Liang JT, Tsao PN, et al. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer[J]. Dis Colon Rectum, 2009, 52(9):1630-1636.
26.	Konstantina A, Lazaris AC, Ioannidis E, et al. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi[J]. Melanoma Res, 2011, 21(5):389-394.
27.	Alpini G, Glaser SS, Zhang J, et al. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer[J]. J Hepatol, 2011, 55(6):1339-1345.
28.	Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic[J]. Lab Invest, 1997, 76(4):517-531.
29.	Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models[J]. Cancer Res, 2006, 66(8):3971-3977.
30.	Hedlund EM, Yang X, Zhang Y, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs[J]. Proc Natl Acad Sci USA, 2013, 110(2):654-659.
31.	Parr C, Watkins G, Boulton M, et al. Placenta growth factor is over-expressed and has prognostic value in human breast cancer[J]. Eur J Cancer, 2005, 41(18):2819-2827.
32.	Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer[J]. Gut, 2005, 54(5):666-672.
33.	Waldner MJ, Neurath MF. Colitis-associated cancer:the role of T cells in tumor development[J]. Semin Immunopathol, 2009, 31(2):249-256.
34.	Li B, Wang C, Zhang Y, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis[J]. Oncogene, 2013, 32(24):2952-2962.
35.	Bagley RG, Kurtzberg L, Weber W, et al. sFLT01:a novel fusion protein with antiangiogenic activity[J]. Mol Cancer Ther, 2011, l0(3):404-415.
36.	Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403:a first-in-human, phaseⅠ, double-blind, dose escalation study directed against placental growth factor in healthy male subjects[J]. Clin Ther, 2011, 33(9):l142-l149.
37.	蘇丹, 張婷婷, 王李杰, 等.胃癌抗血管生成靶向治療的研究進展[J].中國醫藥導報, 2012, 9(9):14-16.
38.	Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism[J]. Am J Cancer Res, 2011, 1(2):265-274.
39.	Yu L, Hales CA. Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice[J]. BMC Cancer, 2011, 11:331.
40.	Sands M, Howell K, Costello CM, et al. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung[J]. Respir Res, 2011, 12:17.
41.	Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy[J]. Proc Natl Acad Sci USA, 2011, 108(28):11590-11595.

1. 胡玉弘, 趙志國, 楊松梅, 等.血管內皮生長因子基因多態性與惡性腫瘤關系研究進展[J].河北醫學, 2010, 16(2):233-235.
2. Fischer C, Jonckx B, Mazzone M, et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels[J]. Cell, 2007, 131(3):463-475.
3. 蔡源源, 李光早.血管內皮生長因子的調控及其作用研究進展[J].組織工程與外科重建雜志, 2010, 7(1):51-54.
4. Maglione D, Guerriero V, Viglietto G, et al. Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14[J]. Oncogene, 1993, 8(4):925-931.
5. De Falco S. The discovery of placenta growth factor and its biological activity[J]. Exp Mol Med, 2012, 44(1):1-9.
6. Errico M, Riccioni T, Iyer S, et al. Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor[J]. J Biol Chem, 2004, 279(42):43929-43939.
7. 時瑩慶, 關巍.胎盤生長因子與低氧的關系研究進展[J].中國醫療前沿, 2013, 8(4):7-8.
8. 何云, 鐘梅, 王晨虹.胎盤生長因子及相關研究[J].醫學綜述, 2011, 17(13):1936-1939.
9. Schomber T, Kopfstein L, Djonov V, et al. Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis[J]. Cancer Res, 2007, 67(22):10840-10848.
10. Shibuya M. Vascular endothelial growth factor receptor-1(VEGFR-1/ Flt-1):a dual regulator for angiogenesis[J]. Angiogenesis, 2006, 9(4):225-230.
11. Boyaud F, Inguimbert N. Soluble fms-like tyrosine kinase-1 antibody for diagnosis purposes (WO2010075475)[J]. Expert Opinion on Therapeutic Patents, 2011, 971-975.
12. Zhou Y, Mcmaster M, Woo K, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome[J]. Am J Pathol, 2002, 160(4):1405-1423.
13. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis:a historical review[J]. Angiogenesis, 2008, 11(3):215-221.
14. 李慧娟, 楊文浩, 崔劉福.胎盤生長因子及其受體在類風濕性關節炎發病機制中的作用[J].中國醫藥, 2010, 5(4):376-377.
15. Yoo SA, Yoon HJ, Kim HS, et al. Role of placenta growth factor and its receptor flt-1 in rheumatoid inflammation:a link between angiogenesis and inflammation[J]. Arthritis Rheum, 2009, 60(2):345-354.
16. Oura H, Bertoncini J, Velasco P, et al. A critical role of placental growth factor in the induction of inflammation and edema formation[J]. Blood, 2003, 101(2):560-567.
17. Odorisio T, Schietroma C, Zaccaria ML, et al. Mice overexpressing placenta growth factor exhibit increased vascularization and vessel permeability[J]. J Cell Sci, 2002, 115(Pt 12):2559-2567.
18. Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF[J]. Cancer Cell, 201l, 19(1):31-44.
19. 閆鵬飛, 李煜.胎盤生長因子的生物活性及其與腫瘤相關作用的研究進展[J].藥物生物技術, 2012, 19(30):265-269.
20. Jain RK, Xu LL. AlphaPlGF:a new kid on the antiangiogenesis block[J]. Cell, 2007, 131(3):443-445.
21. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions[J]. Nat Med, 2001, 7(5):575-583.
22. Papapetropoulos A, García-Carde?a G, Madri JA, et al. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells[J]. J Clin Invest, 1997, 100(12):3131-3139.
23. Autiero M, Waltenberger J, Communi D, et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1[J]. Nat Med, 2003, 9(7):936-943.
24. Marcellini M, De Luca N, Riccioni T, et al. Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor[J]. Am J Pathol, 2006, 169(2):643-654.
25. Wei SC, Liang JT, Tsao PN, et al. Preoperative serum placenta growth factor level is a prognostic biomarker in colorectal cancer[J]. Dis Colon Rectum, 2009, 52(9):1630-1636.
26. Konstantina A, Lazaris AC, Ioannidis E, et al. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi[J]. Melanoma Res, 2011, 21(5):389-394.
27. Alpini G, Glaser SS, Zhang J, et al. Regulation of placenta growth factor by microRNA-125b in hepatocellular cancer[J]. J Hepatol, 2011, 55(6):1339-1345.
28. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic[J]. Lab Invest, 1997, 76(4):517-531.
29. Xu L, Cochran DM, Tong RT, et al. Placenta growth factor overexpression inhibits tumor growth, angiogenesis, and metastasis by depleting vascular endothelial growth factor homodimers in orthotopic mouse models[J]. Cancer Res, 2006, 66(8):3971-3977.
30. Hedlund EM, Yang X, Zhang Y, et al. Tumor cell-derived placental growth factor sensitizes antiangiogenic and antitumor effects of anti-VEGF drugs[J]. Proc Natl Acad Sci USA, 2013, 110(2):654-659.
31. Parr C, Watkins G, Boulton M, et al. Placenta growth factor is over-expressed and has prognostic value in human breast cancer[J]. Eur J Cancer, 2005, 41(18):2819-2827.
32. Wei SC, Tsao PN, Yu SC, et al. Placenta growth factor expression is correlated with survival of patients with colorectal cancer[J]. Gut, 2005, 54(5):666-672.
33. Waldner MJ, Neurath MF. Colitis-associated cancer:the role of T cells in tumor development[J]. Semin Immunopathol, 2009, 31(2):249-256.
34. Li B, Wang C, Zhang Y, et al. Elevated PLGF contributes to small-cell lung cancer brain metastasis[J]. Oncogene, 2013, 32(24):2952-2962.
35. Bagley RG, Kurtzberg L, Weber W, et al. sFLT01:a novel fusion protein with antiangiogenic activity[J]. Mol Cancer Ther, 2011, l0(3):404-415.
36. Martinsson-Niskanen T, Riisbro R, Larsson L, et al. Monoclonal antibody TB-403:a first-in-human, phaseⅠ, double-blind, dose escalation study directed against placental growth factor in healthy male subjects[J]. Clin Ther, 2011, 33(9):l142-l149.
37. 蘇丹, 張婷婷, 王李杰, 等.胃癌抗血管生成靶向治療的研究進展[J].中國醫藥導報, 2012, 9(9):14-16.
38. Tarallo V, Tudisco L, De Falco S. A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism[J]. Am J Cancer Res, 2011, 1(2):265-274.
39. Yu L, Hales CA. Long-term exposure to hypoxia inhibits tumor progression of lung cancer in rats and mice[J]. BMC Cancer, 2011, 11:331.
40. Sands M, Howell K, Costello CM, et al. Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung[J]. Respir Res, 2011, 12:17.
41. Yao J, Wu X, Zhuang G, et al. Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy[J]. Proc Natl Acad Sci USA, 2011, 108(28):11590-11595.

Previous Article
Present Situation and Progress of Diagnosis and Treatment of Gastrointestinal Stromal Tumor
Next Article
腹腔鏡下骶前囊腫切除體會(附1例報道)

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Progress on Placental Growth Factor and Tumor

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content